Asensus Surgical Inc. (ASXC): Price and Financial Metrics


Asensus Surgical Inc. (ASXC): $0.41

-0.02 (-4.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ASXC POWR Grades


  • Growth is the dimension where ASXC ranks best; there it ranks ahead of 80.41% of US stocks.
  • The strongest trend for ASXC is in Quality, which has been heading down over the past 179 days.
  • ASXC ranks lowest in Stability; there it ranks in the 2nd percentile.

ASXC Stock Summary

  • As for revenue growth, note that ASXC's revenue has grown 159.28% over the past 12 months; that beats the revenue growth of 94.99% of US companies in our set.
  • In terms of volatility of its share price, ASXC is more volatile than 95.04% of stocks we're observing.
  • Asensus Surgical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -110.16%, greater than the shareholder yield of only 3.43% of stocks in our set.
  • Stocks that are quantitatively similar to ASXC, based on their financial statements, market capitalization, and price volatility, are PTE, ASTC, OCX, NTRA, and CDNA.
  • Visit ASXC's SEC page to see the company's official filings. To visit the company's web site, go to www.transenterix.com.

ASXC Valuation Summary

  • In comparison to the median Healthcare stock, ASXC's price/sales ratio is 789.87% higher, now standing at 101.
  • Over the past 243 months, ASXC's EV/EBIT ratio has gone down 2.2.
  • Over the past 243 months, ASXC's price/sales ratio has gone up 100.7.

Below are key valuation metrics over time for ASXC.

Stock Date P/S P/B P/E EV/EBIT
ASXC 2021-08-31 101.0 2.6 -8.7 -6.1
ASXC 2021-08-30 95.9 2.5 -8.2 -5.6
ASXC 2021-08-27 100.0 2.6 -8.6 -6.0
ASXC 2021-08-26 100.0 2.6 -8.6 -6.0
ASXC 2021-08-25 101.9 2.7 -8.8 -6.2
ASXC 2021-08-24 103.3 2.7 -8.9 -6.3

ASXC Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -33.71%.
  • The 5 year price growth rate now stands at -98.55%.
  • Its 4 year net income to common stockholders growth rate is now at -198.92%.
ASXC's revenue has moved down $13,284,000 over the prior 34 months.

The table below shows ASXC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 8.232 -40.659 -62.462
2021-09-30 6.863 -40.252 -60.372
2021-06-30 5.106 -40.024 -59.385
2021-03-31 4.659 -44.435 -60.352
2020-12-31 3.175 -46.675 -60.023
2020-09-30 2.756 -48.278 -59.963

ASXC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ASXC has a Quality Grade of D, ranking ahead of 5.14% of graded US stocks.
  • ASXC's asset turnover comes in at 0.038 -- ranking 163rd of 186 Medical Equipment stocks.
  • ARAY, ATRC, and INGN are the stocks whose asset turnover ratios are most correlated with ASXC.

The table below shows ASXC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.038 -0.370 -1.090
2021-06-30 0.034 -0.464 -1.879
2021-03-31 0.041 -0.404 -2.039
2020-12-31 0.040 -0.627 -2.331
2020-09-30 0.035 -4.608 -2.502
2020-06-30 0.048 -3.407 -4.864

ASXC Stock Price Chart Interactive Chart >

Price chart for ASXC

ASXC Price/Volume Stats

Current price $0.41 52-week high $3.75
Prev. close $0.43 52-week low $0.35
Day low $0.41 Volume 1,762,900
Day high $0.44 Avg. volume 2,943,320
50-day MA $0.53 Dividend yield N/A
200-day MA $1.24 Market Cap 97.28M

Asensus Surgical Inc. (ASXC) Company Bio


Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, economic shortcomings in surgery. The Senhance Surgical System features as the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.


ASXC Latest News Stream


Event/Time News Detail
Loading, please wait...

ASXC Latest Social Stream


Loading social stream, please wait...

View Full ASXC Social Stream

Latest ASXC News From Around the Web

Below are the latest news stories about Asensus Surgical Inc that investors may wish to consider to help them evaluate ASXC as an investment opportunity.

Asensus Surgical Q4 2021 Earnings Preview

Asensus Surgical (NYSE:ASXC) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close. The consensus EPS Estimate is -$0.07 (+22.2% Y/Y) and the consensus Revenue Estimate is $1.5M (+35.1% Y/Y). Over the last 2 years, ASXC has beaten EPS estimates 63% of the time and has...

Seeking Alpha | February 27, 2022

Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2021 Financial and Operating Results Conference Call for February 28, 2022

RESEARCH TRIANGLE PARK, N.C., February 22, 2022--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2021 fourth quarter and fiscal year 2021 financial and operating results after the market closes on Monday, February 28, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the

Yahoo | February 22, 2022

Asensus Surgical: Reimagining the Future of Surgery

Setting a new standard with Performance-Guided Surgery New York, New York--(Newsfile Corp. - January 26, 2022) - -- PCG Digital-- Asensus Surgical, Inc. (NYSE American: ASXC) is leading the digital surgical market with a new concept known as Performance-Guided Surgery™. Asensus SurgicalTo view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/6513/111747_fd7e8fe144c8180c_001full.jpgWhen the smart phone in your pocket has more computing power than the standar

Yahoo | January 26, 2022

Asensus Surgical trades in green on prelim FY21 corporate update

In its prelim 2021 year-end corporate update, Asensus Surgical (ASXC) reported 500+ procedures performed globally during Q4 (+25% Y/Y) while 2K+ procedures were performed globally

Seeking Alpha | January 10, 2022

Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update

RESEARCH TRIANGLE PARK, N.C., January 10, 2022--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2021 year-end corporate update.

Yahoo | January 10, 2022

Read More 'ASXC' Stories Here

ASXC Price Returns

1-mo -21.14%
3-mo -38.81%
6-mo -72.85%
1-year -79.40%
3-year -97.56%
5-year -94.27%
YTD -63.06%
2021 77.60%
2020 -57.48%
2019 -95.00%
2018 17.10%
2017 48.46%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8727 seconds.